

UNIVERSITY OF MIAMI
Curriculum Vitae

1. Date: October 20, 2014

PERSONAL

2. Name: Pasquale W. Benedetto, M.D.

3. Home Phone: I

4. Office: University of Miami Sylvester Cancer Center
1475 NW 12th Avenue
Suite 3310
Miami, Florida 33136
Phone: 305-243-6604
FAX: 305-243-4905
Email: pbenedet@med.miami.edu

5. Home Address:

6. Current Academic Rank: Professor of Medicine (Tenured)

7. Primary Department: Medicine, Division of Hematology-Oncology

8. Citizenship: United States

9. Visa Type: N/A

HIGHER EDUCATION

10. Institution

Georgetown University
Washington, D.C.

B.S. Chemistry
Summa Cum Laude

Sept 1968 -- May 1972

Cornell University Medical College, M.D.
New York, New York

Sept 1972 -- May 1976

11. Non-Institutional: None

12. Certification:

Internal Medicine, American Board of Internal Medicine, 1979
Medical Oncology, American Board of Internal Medicine, 1981
Hematology, American Board of Internal Medicine, 1982

Licensure:

New York, 1978 137060
Florida, 1982 0041018

EXPERIENCE

13. Academic

<u>INSTITUTION</u>	<u>RANK</u>	<u>DATES</u>
Johns Hopkins Hospital, Baltimore, MD	Intern	July 1976 - June 1977
Johns Hopkins Hospital, Baltimore, MD	Resident	July 1977 - June 1979
Memorial Sloan-Kettering Cancer Center, New York, NY	Fellow, Medical Oncology	July 1979 - June 1981
Cornell University Medical College, New York, NY	Clinical Instructor	July 1979 - June 1981
Mt. Sinai School of Medicine, New York, NY	Instructor in Medicine	July 1981- June 1982
Beth Israel Medical Center Division of Hematology/Oncology New York, NY	Attending Physician	July 1981- June 1982
University of Miami School of Medicine Department of Oncology	Assistant Professor	July 1982-1987
University of Miami School of Medicine Department of Oncology	Associate Professor	1987-1995
University of Miami School of Medicine Division of Oncology	Professor	1995-Present

University of Miami
School of Medicine
Department of Oncology

Director, Clinical Services 1990-1992

University of Miami
School of Medicine
Department of Medicine

Director, Heme-Onc 1992-2002
Clinic and Day Hospital

CLINICAL TRIALS

Genito-Urinary Cancer Sites:

Kidney Cancer:

Prospective randomized trial of SU0011248 versus Interferon as first line therapy for stage IV Renal cell Carcinoma. (Pfizer) ----completed

Prospective randomized trial of CCI-779 versus Interferon for patients with poor risk Stage IV Renal Cell Carcinoma.(Wyeth) --- completed

AXITINIB (AG-013736) as second line therapy for metastatic renal cell cancer (AXIS TRIAL)
Sponsor Pfizer PI ---completed

A Phase II study of ARQ 197 in patients with microphthalmia transcription factor associated tumors,
Sponsor Arqule Sub PI – completed

An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma, Sponsor Novartis PI- completed

E7080-G000-205: An Open-Label, Multi-center Phase 1b/2 Study of E7080 Alone, and in Combination with Everolimus in Subjects with Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment , Eisai, closed to accrual

SCCC: 2008065 - STUDY VEG108844, A Study of Pazopanib versus Sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma. closed to accrual

A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy

NCI 9144, PhII-121: A Phase II Study of Bevacizumab Alone or in Combination with TRC105 for Advanced Renal Cell Cancer

A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination with Everolimus to Treat Subjects with Advanced Renal Cell Carcinoma

Bladder Cancer:

Phase II trial of Vinflunine as second line therapy for patients with Metastatic Urothelial cancer (Bristol Myers Squibb) closed

A Mutli-center, Randomized Double-Blind Phase II/III Study in the first line treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in patients who are ineligible to receive cisplatin based therapy (VINCENT) (Bristol Myers Squibb) closed

A Phase I/II trial of AEZS-108 in locally advanced unresectable or metastatic LHRH positive urothelial carcinoma patient who have failed platinum based chemotherapy) Aeterna Zentaris open to accrual

Adrenal Carcinoma

Randomized , double blind, placebo controlled , Phase III study of OSI-906 in patients with locally advanced or metastatic adrenocortical carcinoma, Sponsor: OSI PHARMACEUTICALS, INC. completed

Phase I

A Phase I Study of the Alternating Administration of Ixabepilone and Vinflunine every three weeks in patients with Advanced Cancer (Bristol Myers Squibb) closed

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer that Express Nectin-4

Sarcoma

Phase II trial of LY-573636-sodium for patients with unresectable or metastatic soft tissue sarcoma (Lilly) completed

Phase II trial of AMG 479 in relapsed or refractory Ewing's family tumors and desmoplastic small round cell tumors (AMGEN) completed

A Pivotal Trial to determine the efficacy and safety of AP23573 when administered as

maintenance therapy tp patients with metastatic soft tissue or bone sarcomas; Sponsor ARIAD completed

An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen; Sponsor GSK closed

A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma closed to accrual

A Phase II randomized, double-blind, placebo controlled study to assess safety, tolerability and effect on tumor size of MCS110 in patients with pigmented villonodular synovitis (PVNS)

A Phase I Trial of Dendritic Cell Vaccination With and Without Inhibition of Myeloid Derived Suppressor Cells by Gemcitabine Pre-Treatment For Children And Adults With Sarcoma

A dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl-inositol 3-kinase (PI3K) inhibitor BYL719 in patients with gastrointestinal stromal tumor (GIST) who failed prior therapy with imatinib and sunitinib

A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib (Bayer) to open for accrual

A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with Metastatic or Locally Advanced (Unresectable) Chondrosarcoma Infinity Pharmaceuticals completed

An Open label Treatment Protocol for the Use of Voraxaze as Adjunctive Treatment for Patients Experiencing or at Risk of Methotrexate toxicity (Protherics)

Prospective, Multicenter, Randomized, Open-Label, Active-controlled, Phase III Study to compare the efficacy and safety of masatinib to sunitinib in patients with Gastrointestinal Stromal Tumor (GIST) resistant to imatinib. AB Science open to accrual

A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment AB Science open to accrual

14. Non-Academic: NONE

15. Military: NONE

PUBLICATIONS

16. Books and Monographs published:

Benedetto, P.: "Genitourinary Cancer" in Oncology. Elsevier, North Holland: New York, 1985.

17. Juried or refereed journal articles and exhibitions:

- 1) Bynum, T.E. **Benedetto, P.W.** Zerhouni, E.A. Copeland, B.E. Pancreatic Pseudocyst. Johns Hopkins Medical Journal, 143 (3):109-113, 1978.
- 2) McGoon, M.D. **Benedetto, P.W.** Greene, B. Complications of Percutaneous Central Venous Catheterization. A Report of Two Cases and Review of the Literature. Johns Hopkins Medical Journal, 145:1-6, 1979.
- 3) **Benedetto, P.W.** Ahmed, T. Yagoda, A. Needles, B. Watson, R.C. Phase II trial of 4'Epi-Adriamycin for Advanced Hypernephroma. Am. J. Clin. Oncol. 6:553-554, 1983.
- 4) Ahmed, T. **Benedetto, P.** Yagoda, A. Watson, R.C. Scher, H.I. Herr, H.W. Sogani, P.C. Whitmore, W.F. Pertschuk, L. Estrogen, Progesterone and Androgen-Binding Sites in Renal Cell Carcinoma: Observations Obtained in Phase II Trial of Flutamide. Cancer, 54(3):477-481, 1984.
- 5) Kris, M.G. Mertelsmann, R. Jhanwar, R. Chaganti, R. Szatrowski, J.H. Gee, T.S. Arlin, Z. Kempin, S. **Benedetto, P.** Clarkson, B. Relationship of Auer Rods and Chromosome Findings to Outcome in Eighty-Nine Adults with Acute Non-Lymphoblastic Leukemia. Leukemia Research, 9 (10):1231-1235, 1985.
- 6) **Benedetto, P.** Mertelsmann, R. Szatrowski, T.H. Andreeff, M. Gee, T. Arlin, Z. Kempin, S. Clarkson, B. Prognostic Significance of Terminal Deoxynucleotidyl Transferase (TdT) Activity in Acute Non-Lymphoblastic Leukemia. Journal of Clinical Oncology, 4 (4):489-495, (April) 1986.
- 7) Sridhar, K.S. Varki, J. Donnelly, E. Davila, E. **Benedetto, P.** Hilsenbeck, S. Thurer, R.J. Rao, R.K. Fountzilas, G. Beattie, E. Toxicity of FED Chemotherapy in Non-Small Cell Lung Cancer. Am. J. of Clin. Oncol. (CCT)10 (6):499-506, 1987.
- 8) Goldenberg, A. Kelsen, D. **Benedetto, P.** A Phase II Trial of Mitoxantrone in Advanced Gastric Cancer. Oncology 45:273-275, 1988.
- 9) Sridhar, K.S. Thurer, R. Kim, Y. Fountzilas, G. Davila, E. Donnelly, E. Charyulu, KKN. Saldana, M.J. Thompson, T. **Benedetto, P.** Raskin, N. Beattie, E.J. Multimodality Treatment of

Non-Small Cell Lung Cancer: Response to Cis-Platin, VP-16, and 5-FU Chemotherapy and to Surgery and Radiation Therapy. *Journal of Surgical Oncology*, 38 193-215, 1988.

- 10) Sridhar, KS. Samy, TS. Koch, G. Agarwal, R. Duncan, RC. Glanz W. **Benedetto P.** Feun, L. Savaraj, N. Gross, J. Krishan, A. Zubrod, C.G. Phase I Study of 4-O-Tetrahydropyranyl Adriamycin, Pirarubicin Workshop, 15th International Congress of Chemotherapy. *Advances in Experimental and Clinical Chemotherapy* p 11-26, May 1988.
- 11) Sridhar KS. **Benedetto, P.** Otrakji, CL. Charyulu, KK. Response of Eccrine Adenocarcinoma to Tamoxifen. *Cancer* 64:18-22, 1989.
- 12) Berger, JR. Snodgrass, S. Glaser, J. Post, JJ. Norenberg, M. **Benedetto, P.** Multifocal Fibrosclerosis with Hypertrophic Intracranial Pachymeningitis. *Neurology* 39:1345-1349, 1989.
- 13) Hussein, AM. **Benedetto, P.** Sridhar, KS. Chemotherapy with Cis-Platin and 5-Fluorouracil in Penile and Urethral Squamous Cell Carcinoma. *Cancer* 65:433-438, 1990.
- 14) Hussein, AM. Feun, LG. Sridhar, KS. Otrakji, CL. Garcia-Moore, M. **Benedetto, PW.** Small cell carcinoma of the large intestine presenting as central nervous system signs and symptoms. Two case reports with literature review. *Journal of Neuro-Oncology* 8:269-274, 1990.
- 15) Mmaysneh, W. Malinin, T. **Benedetto, P.** Ghandur-Mnaysneh, L. Pelvic Allografts. *Clin Orth.* 255:128-132, 1990.
- 16) Essinfeld, H. Manivel, C. **Benedetto, PW.** Albores-Saavedra, J. Small cell carcinoma of the renal pelvis: A clinicopathological, morphological and immunohistochemical study. *J. of Urol.* 144:344-347, 1990.
- 17) Sridhar, KS. Samy. AS. Agarwal, RP. Duncan, RC. **Benedetto, PW.** Krishan, AG. Vogel, CV. Feun, LG. Savaraj, NM. Richman, SP. Zubrod, CG. Phase I study of Pirarubicin (4'-o-tetrahydropyranyl adriamycin): Clinical Pharmacology and Pharmacokinetics. *Cancer* 66:2082-2091, 1990.
- 18) Hussein, AM. Feun, LG. Sridhar, KS. **Benedetto, PW.** Waldman, S. Otrajki, CL. Combination chemotherapy and radiotherapy for small cell carcinoma of the esophagus: A case report of long term survival and review of the literature. *Am J. Clin Onc.* 13:369, 1990.
- 19) Sridhar, KS. Hussein, AM. **Benedetto, PW.** Ardalán, B. Savaraj, N. Richman, SP. Phase II Trial of 4-O-tetrahydropyranyl-adriamycin in Head and Neck Carcinoma. *Cancer* 66(10):2082-2091, 1990.
- 20) Sridhar, KS. Hussein, AM. **Benedetto, PW.** Waldman, SM. Feun, LG. Savaraj, NM. Richman, SP. Ardalán. B. Desai, P. Phase II Trial of Mitoxantrone in Head and Neck Carcinoma. *American Journal of Clinical Oncology*, 14(1):298-304, 1991.

- 21) Feun, LG. Savaraj, NM. **Benedetto, PW.** Hanlon, J. Sridhar, KS. Collier, M. Richman, SP. Liao, SH. Clendenin, N. Phase I Trial of Piritrexim Capsules Using Prolonged, Low-Dose Oral Administration for the Treatment of Advanced Malignancies. *J Natl Cancer Inst* 83:51-55, 1991.
- 22) Mnaymneh, W. Malinin, T. Ghandur-Mnaymneh, L. **Benedetto, P.** Scapular Allografts, A Report of Two Cases. *Clinical Orthopaedics and Related Research* 262:124-128, 1991.
- 23) Serafini, AN. Vargas-Cuba, R. **Benedetto, P.** Legaspi, A. Feun, L. Robinson, D. Ardalan, B. Dewanjee, MK. Sevin, BU. Averette, H, Sfakianakis, G. Clinical Experience in Utilizing Radiolabeled Monoclonal Antibodies. *Antibody, Immunoconjugates, and Radiopharmaceuticals* Vol 4, No. 1, 77-83, 1991.
- 24) Neidhart, JA. Anderson, SA. Harris, JE. Rinehart, JJ. Laszlo, J. Dexeus, F. Einhorn, L. Trump, DL. **Benedetto, PW.** Tuttle, RL. Smalley, RV. Vinblastine Fails to Improve Response of Renal Cancer to Interferon Alfa-n1: High Response Rate in Patients With Pulmonary Metastases. *J Clin Oncol* 9:832-837, 1991.
- 25) Ardalan, B. Chua, L. Tian, E. Reddy, R. Sridhar, K. **Benedetto, P.** Richman, S. Legaspi, A. Waldman, S. Morrell, L. Feun, L. Savaraj, N. Livingstone, A. A Phase II Study of Weekly 24 Hour Infusion With High Dose 5-Fluorouracil (5-FU) With Leucovorin (LV) in Colorectal Carcinoma. *Journal of Clinical Oncology* 9:625-630, 1991.
- 26) Serafini, AN. Vargas-Cuba, R. **Benedetto, P.** Ardalan, B. Garrido, J. Robinson, D. Moffat, F, Pinsky, CM. Technetium-99m-Labeled Fab' Fragment of Anti-CEA Monoclonal Antibody for the Radioimmunodetection of Colorectal Adenocarcinoma. *Antibody, Immunoconjugates, and Radiopharmaceuticals* 4(4),561-568, 1991.
- 27) Ardalan, B. Sridhar, K. **Benedetto, P.** Richman, S. Waldman, S. Morrell, L. Feun, L. Savaraj, N. Fodor, M. and Livingstone, A. Phase I, II study of high dose 5-Fluorouracil and High- Dose Leucovorin with Low Dose Phosphonacetyl-L-Aspartic Acid in Patients With Advanced Malignancies. *Cancer* 68: 1242-1246, 1991.
- 28) Ardalan, B. Sridhar, K. Reddy, R. **Benedetto, P.** Richman, S. Waldman, S. Morrell, L. Feun, L. Savaraj, N. Livingstone, A. Phase I Study of High Dose 5-Fluorouracil and High Dose Leucovorin with Low Dose Phosphonacetyl-L-Aspartic Acid with Advanced Malignancies. Section B: Biochemical Modification of Therapeutic Response. *Int. J Radiation Oncology Biol. Phys.* 22(3):511-514, 1992.
- 29) Sridhar, Ks. Hussein, AM. **Benedetto, P.** Ardalan, B. Savaraj, N. Richman, S. Phase II Trial of 4'-O-Tetrahydropyranyl adriamycin (Pirarubicin) in Head and Neck Carcinoma. *Cancer* 70(6):1591-1597, 1992.

- 30) Sridhar, KS. Krishan, A.Samy, TSA. Sauerteig, A. Wellham, LL. McPhee, G. Duncan, RC. Anac, SY. Ardalán, B. **Benedetto, PW**. Prochlorperazine as a doxorubicin-efflux blocker: Phase I clinical and pharmacokinetics studies. *Cancer chemother pharmacol* 31:423-430, 1993.
- 31) Berger, JR. Flaster, M. Schatz, N. Droller, D. **Benedetto, P**. Poblete, R. Post, MJD. Cranial Neuropathy Heraldng Otherwise Occult AIDS-Related Large Cell Lymphoma. *J Clin Neuro-Ophthalmology* 13(2):113-118, 1993.
- 32) Savaraj. N. Feun, L. Blyden, G. Yrizarry, J. Hsiang, J. Curtas, J. Waldman, S. Post, JD. **Benedetto, P**. Landy, H. Guerra, Jr. J. A Pilot Clinical and Pharmacological Study of Intra-arterial Infusion of Thiotepa. *Cancer Biotherapy* Vol 8, No. 1:37-42, 1993.
- 33) Feun, LG. Blyden, G. Yrizarry, J. Dorvil, M. Waldman, S. **Benedetto, P**. Donnelly, E. Curtas, J. George, M. Savaraj, N. Clinical and Pharmacological Study of Intrahepatic Artery Infusion of Thiotepa. *Cancer Biotherapy* Vol 8, No. 1:43-48, 1993.
- 34) Sridhar, KS. Krishan, A. Samy, TSA. Duncan, RC. Sauertig, A. McPhee, GV. Auguste, ME. **Benedetto, PW**. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-eflux blocker. *Cancer Chemother Pharmacol* 34:377-384, 1994.
- 35) Abbas, F. Civantos, F. **Benedetto, P**. Soloway, M. Small Cell Carcinoma of the Bladder and Prostate. *Urology* 46(5): 617-630, 1995.
- 36) Whitehead, RP. Wolf, MK. Solanki, DL. Hemstreet, GP. **Benedetto, P**. Richman, SP. Flanigan, RC. Crawford, ED. A Phase II Trial of Continuous-Infusion Recombinant Interleukin-2 in Patients with Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study. *Journal of Immunotherapy* 18(2):104-114, 1995.
- 37) Meldrum, Melissa. Tse, David. **Benedetto, Pasquale**. Neoadjuvant Intracarotid Chemotherapy for Treatment of Advanced Adenocystic Carcinoma of the Lacrimal Gland. *Arch. Ophthalmol.* 116:315-321, 1998.
- 38) Wolfson AH, **Benedetto PW**, Mnaymneh W, Moffat FL, Robinson DS, Boyer C, Raub WA Jr, Duncan RC, Markoe AM. Does a radiation dose response relation exist concerning survival of patients who have soft tissue sarcomas of the extremities? Radiation dose response relation for soft tissue sarcomas. *Am J Clin Oncol Jun* 21(3): 270-4, 1998.
- 39) Johnson TE, Tse DT, Byrne GE Jr, Restrepo A, Whitcomb CC, Voigt W, **Benedetto P**, Curtin V. Ocular-adnexal lymphoid tumors: a clinicopathological and molecular genetic study of 77 patients. *Ophthal Plast Reconstr Surg* 15 (3): 171-9, May 1999.
- 40) **Benedetto, Pasquale**. Chemotherapy of Testis Cancer. *Cancer Control, Journal of the Moffitt Cancer Center*, 6(6):549-559, 1999.

- 41) Bathe OF, Levi D, Caldera H, Franceschi D, Raez L, Patel A, Raub WA Jr, **Benedetto, P**, Reddy R, Hutson D, Sleeman D, Livingstone AS, Levi JU. Radical resection of periampullary tumors in the elderly: evaluation of long term results. *World J Surg* 24(3): 353-8, Mar 2000.
- 42) Delacruz V, Jorda M, Gomez-Fernandez C, **Benedetto P**, Ganjei P. Fine-needle aspiration diagnosis of angiosarcoma of the spleen: a case report and review of the literature. *Arch Pathol Lab Med* 129(8): 1054-6, Aug 2005.
- 43) Tse DT, **Benedetto P**, Dubovy S, Schiffman JC, Feuer WJ. Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. *Am J Ophthalmol* 141(1) 44-53, Jan 2006.
- 44) Tse DT, Finkelstein SD, **Benedetto P**, Dubovy S, Schiffman JC, Feuer WJ. Microdissection genotyping analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma *Am J Ophthalmol* 141(1) 54-61, Jan 2006.
- 45) Tse DT, **Benedetto P**, Morcos JJ, Johnson TE, Weed D, Dubovy S. An atypical presentation of adenoid cystic carcinoma of the lacrimal gland *Am J Ophthalmol* 141(1) 187-9, Jan 2006.
- 46) Vega J, Bouzari N, Romanelli P, Lanuti EL, **Benedetto, P**, Green A, Rongioletti F, Kerdel F. Necrolytic Migratory Erythema Associated with Nonfunctional Islet Cell Tumor. *International Journal of Dermatology* 47:332–334, 2008
- 47) Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, **Benedetto PW**, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M, Tolcher A. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. *J Clin Oncol*. 2012 May 20;30(15):1849-56. doi: 10.1200/JCO.2011.37.2359. Epub 2012 Apr 16. PMID: 22508822
- 48) Socola F, Loaiza-Bonilla A, **Benedetto P**. Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication. *Case Rep Oncol Med*. 2012;2012:390702. doi: 10.1155/2012/390702. Epub 2012 Dec 26. PMID: 23326741
- 49) Tse DT, Kossler AL, Feuer WJ, **Benedetto PW**, Long-term Outcomes of Neoadjuvant Intra-arterial Cytoreductive Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma. *Ophthalmology*. 2013 Jul;120(7):1313-23. doi: 10.1016/j.ophtha.2013.01.027. Epub 2013 Apr 9. PMID: 23582989
- 50) Tse DT, Kossler AL, Feuer WJ, **Benedetto PW**. Author reply: To PMID 23582989 *Ophthalmology*. 2014 Jan;121(1):e8-e10. doi: 10.1016/j.ophtha.2013.11.012. Epub 2013 Nov 20. No abstract available. PMID: 24268860

- 51) Mahmoud O, Dosch A, Kwon D, Pitcher JD, Conway S, **Benedetto P**, Fernandez G, Trent J, Temple HT, Wolfson AH. The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome. *Am J Clin Oncol*. 2014 May 29. [Epub ahead of print], PMID: 24879472

Collaborative Studies:

- 52) Gastrointestinal Tumor Study Group. Phase II Trials of Maytansine, Low-Dose Chlorozotocin and High-Dose Chlorozotocin as Single Agents Against Advanced Measurable Adenocarcinoma of the Pancreas. *Cancer Treat Rep* 69: 417-420, 1985.
- 53) Gastrointestinal Tumor Study Group. Phase II Trials of Hexamethylmelamine, Dianhydrogalacticol, Razoxane and B-2'-De-oxythioguanosine As Single Against Advanced Measurable Tumors of the Pancreas. *Cancer Treat Rep*. 69:713-716,1985.
- 54) Moertel, CG. Stablein, DM. for Gastrointestinal Tumor Study Group (GITSG). Phase II Studies of Drug Combinations in Advanced Pancreatic Carcinoma: Fluorouracil Plus Doxorubicin Plus Mitomycin C (FAM) and Two Regimens of Streptozotocin Plus Mitomycin C Plus Fluorouracil (SMF). *Journal Clinical Oncology*. Vol 4:1974, 1986.
- 55) Gastrointestinal Tumor Study Group: Further Evidence of Effective Adjuvant Combined Radiation and Chemotherapy Following Curative Resection of Pancreatic Cancer. *Cancer* 59:2006-2010, 1987.
- 56) Gastrointestinal Tumor Study Group (GITSG). Phase II trials of the single agents Baker's Antifol, Diaziquinone and Epirubicin in Advanced Pancreatic Cancer. *Cancer Treatment Reports* 7 (9), 865-867, 1987.
- 57) Gastrointestinal Tumor Study Group. Treatment of Locally Unresectable Carcinoma of the Pancreas: Comparison of Combined Modality Therapy (Chemotherapy plus Radiotherapy) to Chemotherapy Alone. *JNCI* 80 (10), July 20, 1988.
- 58) Bruckner, HW. Stablein, DM. for the Gastrointestinal Tumor Study Group (GITSG). Triazinate and Platinum Efficacy in Combination with Fluorouracil and Doxorubicin. Results of a Three-Arm Randomized Trial in Metastatic Gastric Cancer. *JNCI* 80:1011-1015, 1988.
- 59) Gastrointestinal Tumor Study Group (GITSG). Ifosfamide is an Inactive Substance in the Treatment of Pancreatic Carcinoma. *Cancer* 64:2010-2013, 1989.
- 60) Gastrointestinal Tumor Study Group. The Modulation of Fluorouracil with Leucovorin in Metastatic Colorectal Carcinoma: A Prospective Randomized Phase III Trial. *J. Clin. Onc.* 7(10):1419-1426, 1989.

- 61) Gastrointestinal Tumor Study Group. The Concept of Locally Advanced Gastric Cancer. *Cancer* 66:2324-2330, 1990.
- 62) Gastrointestinal Tumor Study Group. A prospective trial of recombinant human interferon Alpha 2b in previously untreated patients with hepatocellular carcinoma. *Cancer* 66:135-139, 1990.
- 63) Seydel, HG. Stablein, DM. Leichman, LP. Kinzie, JJ. Thomas, P. Hyperfractionated Radiation and Chemotherapy for Unresectable Localized Adenocarcinoma of the Pancreas: The Gastrointestinal Tumor Study Group Experience. *Cancer* 65:1478-1482, 1990.
- 64) Gastrointestinal Tumor Study Group. Adjuvant Therapy with Hepatic Irradiation plus Fluorouracil in Colon Carcinoma. *Int. J. Radiation Oncology Biol. Phys.* 21(5):1151-1156, 1991.
- 65) Gastrointestinal Tumor Study Group. Radiation Therapy and Fluorouracil With or Without Semustine for the Treatment of Patients with Surgical Adjuvant Adenocarcinoma of the Rectum. *J Clin Oncol* 10:549-557, 1992.
- 66) Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim S, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus Interferon Alfa in Metastatic Renal Cell Carcinoma, *N Engl J Med* 356:115-124, Jan 2007
- 67) Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Brodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf I, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer R for the Global ARCC Trial. Temsirolimus, Interferon Alfa, or Both for Advanced Renal Cell Carcinoma. *NEJM* 356:2271-81, 2007.
- 68) Theodore F. Logan, Cezary Szczylik, Nizar M. Tannir, **Pasquale Benedetto**, Anatoly Makhson, David McDermott, Paul Ruff, Juraj Mikulás, Janice P. Dutcher, Anna Berkenblit, Laure Galand, Mizue Krygowski, Gary Hudes Effect of Nephrectomy Status on Temsirolimus Efficacy in Patients with Poor-Prognostic Renal Cell Cancer, submitted to *Cancer*
- 69) Arango, Belisario, **Benedetto, Pasquale**, Successful Treatment of Unresectable Immature Teratoma in male patients (in process)

18. **Other works and publications:**

BOOK CHAPTERS

Pasquale Benedetto "Testicular Mass" in *Clinical hematology and oncology.* ed by B. Furie, et al, Churchill Livingstone, 2003, 179

Pasquale Benedetto "Soft Tissue Sarcomas " in Clinical hematology and oncology. ed by B. Furie, et al, Churchill Livingstone, 2003, 1038

ABSTRACTS:

- 1) **Benedetto, P.** Yagoda, A. Watson, RC. Sogani, P. Neri, RO. Pertschuk, LP. Fishman, J. Bradlow, JL. Phase II Trial of Flutamide in Hypernephroma, Correlation with Hormone Receptor Sites. Proc. American Assoc. Cancer Res. and American Soc. Clin. Oncology, C-522, 1981 (Abs).
- 2) **Benedetto, P.** Ahmed, T. Needles, B. Yagoda, A. Watson, RC. Phase II Trial of 4' Epi-Adriamycin in Hypernephroma. Proc. Amer. Soc. Clin. Oncology,2:114, 1982 (C-441).
- 3) **Benedetto, P.** Mertelsmann, R. Ciobanu, N. Gee, TS. Arlin, Z. Kempin, S. Clarkson, B. Prognostic Significance of Terminal Deoxynucleotidyl Transferase (Tdt) Activity in Adult Nonlymphoblastic Leukemia (ANLL): Evidence for Biphenotypic Leukemias. Proc. Amer. Assoc. Cancer Res. 451, 1982.
- 4) Wittes, R. Jain, K. Kaufman, R. Currie, V. Hakes, T. Bosl, G. **Benedetto, P.** and Young, C. A Randomized Comparison of 4' EPIDOXORUBICIN (4'ED) and DOXORUBICIN (DOX) in Advanced Breast Cancer. Proc. Amer. Soc. Clin. Onc.,C-426,1983.
- 5) Jain, K. Wittes, R. **Benedetto, P.** Kaufman, R. Currie, V. Hakes, T. Bosl, G. A Randomized Comparison of Weekly (Arm I) vs. Monthly (Arm II) DOXORUBICIN (DOX) in Combination with Mitomycin (MMC) in Advanced Breast Cancer. Proc.Amer. Soc.Clin. Onc., C-427, 1983.
- 6) **Benedetto, P.** Davila, E. and Solomon, J. Chronic Continuous Systemic Infusion of 5-Fluorouracil (CCI-5-FU) in the Treatment of Metastatic Colorectal Carcinoma (CRC). Proc. Amer. Soc. Clin. Onc., C-556, 1984.
- 7) Crawford, ED. Davis, MA. Ahmann, FR. Levasseur, YJ. Garfield, DH. Friedman, S. Kreis, W. Warden, SS. Ledes, C. Murray, FP. Hueser, JH. Murray, CL. Garnick, MB. Williams, RD. and **Benedetto, P.:** Aminoglutethimide in Metastatic Adenocarcinoma of the Prostate. Proc. Amer. Soc. Clin. Onc., C-616, 1984.
- 8) Sridhar, KS. Varki, J. Donnelly, E. Davila, E. **Benedetto, P.** 5-Fluorouracil Infusion (FU), Etoposide (VP-16) and Cisplatin (DDP)Combination (FED) Chemotherapy (CT) in Non Small Cell Lung Cancer (NSLC). Proc. AACR, 677. March, 1985.
- 9) Sridhar, KS. Groh, E. Varki, J. Davila, E. Donnelly, E. **Benedetto, P.** Beattie, E.J. 5-Fluorouracil (FU), Etoposide(VP-16)and Cisplatin(DDP) Combination (FED)

chemotherapy(CT) in non-small cell lung cancer (NSLC). IV World Conference in Lung Cancer, Toronto, 1985 (Slide presentation).

- 10) Davila, E. Gorowski, E. Vogel, CL. Sridhar, K., **Benedetto, P.** Krishan, A. Mian, A. Royer, GL. Phase I Trial of High Dose Cytosine Arabinoside (HiDAC) in Solid Tumors. European Conf. Clin. Oncol., 1985 (Slide presentation).
- 11) **Benedetto, P.** Bogos, M. Morillo, G. Sfakianakis, G. Chronic Continuous Infusion 5-FU in Previously Untreated Patients with Measurable Colorectal Cancer. Proc. ASCO, #353, 1986.
- 12) Sridhar, KS. Samy, A. Kosinski, J. **Benedetto, P.** Feun, L. Gross, J. Owen, P. Zubrod, CG. A Phase I Study of I.V. Bolus Q3W 4'-O-TETRAHYDROPYRANYLADRIAMYCIN (THP-ADM) Chemotherapy (CT). Proc. ASCO, Vol 6, p. 28, (#107), 1987.
- 13) Sridhar, KS. Samy, TSA. Agarwal, RP. Duncan, RC. **Benedetto, P.** Feun, LG. Krishan, A. Zubrod, CG. Phase I Study of 4'-O-tetrahydropyranyladriamycin (THP-ADR). Proc. AACR 20. 185, 1988 (Abs #736).
- 14) Feun, LG. Clendennin, NJ. Savaraj, N. **Benedetto, P.** Sridhar, K. Hanlon, J. Collier, M. Richman, S. University of Miami and Burroughs Wellcome Co., Research Triangle Park, N.C.. Phase I Trial of Piritrexim (BW 301, PTX) Capsules Using Prolonged Low-Dose Administration. Proc. AACR 29:227, 1988 Abs #903).
- 15) **Benedetto, P.** Mnaymneh, W. Ghandur-Mnaymneh, L. Tehrenzadeh, J. Yrizarry, J. Morillo, G. Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcomas (ETS). Proc ASCO 8:323, 1989.
- 16) Ardalan, B. Hussein, A. Sklaver, L. Reddy, R. **Benedetto, P.** Sridhar, KS. Richman, S. Feun, L. Savaraj, N. Waldman, S. Hung, S. Chemotherapy (C) of Advanced Carcinoma (Ca) with 5-Fluorouracil(FU) and Leucovorin (LV). Proc ASCO 8:116, 1989.
- 17) Sridhar, KS. Thurer, RJ. Savaraj, N. **Benedetto, P.** Feun, L. Waldman, S. Schwade, J. Pre- and Postoperative (OP) Adjuvant Chemotherapy (CT) in Locally Advanced Non-Small Cell Lung Carcinoma. Proc ASCO 8:237, 1989.
- 18) Ardalan, B. Hussein, A. Shanahan W. Aspinall, R. Gardiner, P. Shield, M. Richman, S. Sridhar, K.S. **Benedetto, P.** Feun, L. Waldman, S. Glantz, A. Sklaver, L. Phase I Continuous (Cont) Intravenous (IV) infusion of Carbetimer (CBT) in Refractory Malignancies. Proc AACR 30:283, 1989.
- 19) Savaraj, MN. Feun, LG. Blyden, G. Dorvil, M. Yrizarry, JM. Donnelly, E. Post, J. Curtas, J. Waldman, S. **Benedetto, P.** Clinical and Pharmacological Study of Intra-arterial (IA) infusion of Thiotepa in localized extrahepatic tumors (LET) VA Medical Center, Florida A & M and U

- of Miami Sylvester Comp. Cancer Ctr. Miami, Fl. 33136. Pro. ASCO Vol 9, 97, 1990 (Abs # 337).
- 20) K S Sridhar, AM Hussein, A Barmann, **P Benedetto**, B Ardalán, S Waldman, SP Richman, L Feun, N Savaraj, L Morrell, E Donnelly. Phase II Study of Q3 week IV Bolus Pirarubicin (4'-O-tetrahydropyranyladriamycin) in head and neck carcinoma (H & N CA). Sylvester Cancer Center, U of Miami School of Medicine and Va Medical Center, Miami, Fl. Pro. ASCO Vol 9:179, 1990 (abs #694)
 - 21) Serafini, AN. Vargas-Cuba, R. **Benedetto, P.** Ardalán, B. Legaspi, A. Robinson, D. Garrido, J. Perez, L. Sfakianakis, GN. Pinsky, C. Tc99m Labeled Fab' fragment anti-CEA antibody (IMMU-4) for the radio-immunodetection(RAID) of Colorectal Carcinoma. Submitted to the Third Conference on Radioimmunodetection and radioimmunotherapy of Cancer.
 - 22) R., Canetta. **P. Benedetto.** C. Ehrlich. D. McFadden. R. Motzer. S. Florentine. Administration of Carboplatin followed by dialysis to Anuric Patients. Bristol Myers Squibb, PRDD, Wallingford, USA Submitted to the IXth Congress of the European Association of Urology, June 1990.
 - 23) Sridhar, KS. Krishan, A. Anac, S. **Benedetto, P.** Kolonias, D. Richman, SP. Ardalán, B. Barmann, A. Waldman, S. Feun, L. Phase I Study of IV Prochlorperazine(P) and Doxorubicin (D). Proc AACR , 1990.
 - 24) Clendeninn, N. Savaraj, N. **Benedetto, P.** Waldman, S. Antunez, J. Donnelly, E. Offenhauser, K. Feun, LG. Compassionate Use of oral piritrexim in advanced bladder cancer: An effective drug after progression on MVAC chemotherapy? Proc. AACR, 1991. (Poster Presentation)
 - 25) **Benedetto, P.** Mnaymneh, W. Ghandur-Mnaymneh, L. Joppert, M. Robinson, D. Morillo, G. Neoadjuvant Chemotherapy (Neo-RX) in the Management of Appendicular Soft Tissue Sarcoma (STS) Proc. Third Intl Congress on Neoadjuvant Chemotherapy 1991. Paris, France (Accepted for Presentation)
 - 26) Sridhar, KS. Krishan, A. Anac, S. Duncan, R. **Benedetto, P.** Ardalán, B. Samy, T. Feun, L. Savaraj, N. Richman, S. Phase I Study of Doxorubicin plus Prochlorperazine as a resistance modifier. Proc. ASCO, 106, 1991, (abs# 294).
 - 27) Ardalán, B. Sridhar, K. Richman, S. **Benedetto, P.** Morrell, L. Feun, L. Savaraj, N. Waldman, S. Addition of High-Dose Leucovorin (LV) to High Dose Infusion of 5-Fluorouracil (5-FU) and Low Dose PALA: Effective in Pancreatic Cancer Therapy. Proc. ASCO, 139, 1991, (abs #423).
 - 28) Morrell, L. Ardalán, A. Richman, S. Waldman, S. Feun, L. Sridhar, K. **Benedetto, P.** A Phase II Study of Thiotepa (TP) in Combination with 5-Fluorouracil (FU) and Leucovorin (LV) in Patients with Advanced Breast Cancer (BC). Proc. ASCO, 62, May 991, (abs #124).

- 29) Sridhar, KS. Krishan, A. Samy, A. Duncan, R. **Benedetto, P.** Ardalan, B. Phase I study of Prochlorperazine in Combination with Doxorubicin in Cancer Patients. Proc. Amer Coll Clin Pharm, 1991.
- 30) Serafini, A. Vargas-Cuba, R. Garrido, J. **Benedetto, P.** Ardalan, B. Robinson, D. Moffat, F. Pinsky, C. Clinical Relevance of Tc-99m-Fab' Anti-CEA Monoclonal Antibody (MoAb) in the early detection of Recurrence of Colorectal Cancer. Proc. Am Gastro Assoc. Vol 100, No. 5, 1991. (Accepted for presentation)
- 31) Berger, JR. Flaster, M. Droller, D. Schatz, N. **Benedetto, P.** Poblete, R. Cranial Neuropathy Heraldng AIDS-Related Large Cell Lymphoma. Proc. Amer. Neuro. Assoc., 1991. (Accepted for Presentation).
- 32) Morrell L, Ardalan B, Richman S, Waldman S, Feun L, Sridhar K, **Benedetto P.** A phase II study of thiotepa (TP) in combination with 5-fluorouracil and leucovorin (LV) in patients with advanced breast cancer (BC). ASCO Abstract, 1991.
- 33) Ardalan, B. Sridhar, K. Reddy, R. **Benedetto, P.** Richman, S. Waldman, S. Morrell, L. Feun, L. Savaraj, N. Livingstone, A. Phase I and II study of high dose 5-fluorouracil and high dose leucovorin with low dose PALA in patients with advanced malignancies. Presented to the Seventh International Conference on Chemical Modifiers of Cancer Treatment, Feb 1991.
- 34) Kodali, V. Reddy, R. Parker, T. Livingstone, A. Levi, J. Ardalan, B. **Benedetto, P.** Silva, M. Jeffers, L. Schiff, E. Role of Laparoscopy in Pancreatico-biliary Malignancy. Proc of Am Soc for GI Endo, May 1992.
- 35) Sridhar, KS. Doria, R. Hussein, A. Waldman, S. **Benedetto, P.** Activity and Toxicity of 4'-O-Tetrahydropyranyl-Adriamycin (Pirarubicin) in Malignant Mesothelioma. Proc ASCO, 356, May 1992, (abs # 1225).
- 36) Morrell, L. Richman, S. Waldman, S. Hurley, J. Otrajki, C. Sridhar, KS. **Benedetto, P.** Feun, L. Ardalan, B. Donofrio, K. Liebman, A. Hanlon, J. Methotrexate, Vinblastine, Doxorubicin, Cisplatin (MVAC) as Neoadjuvant for Locally Advanced Breast Cancer (LABC). Proc. ASCO, 84, May, 1992, (abs # 162).
- 37) Tian, E. Ardalan, B. **Benedetto, P.** Feun, L. Morrell, L. Waldman, S. Hurley, J. Savaraj, N. Richman, S. A Phase II Study of Short Term Protracted Infusion of High Dose 5-Fluorouracil (5-FU) with Leucovorin (LV) and Low Dose Phosphonacetyl-L-Aspartic Acid (PALA) in Pancreatic Carcinoma. Proc ASCO, 184, May, 1992, (abs #550).
- 38) Ardalan, B. Donofrio, K. Sridhar, KS. Feun, L. Savaraj, N. **Benedetto, P.** Morrell, L. Waldman, S. Reddy, R. Livingstone, A. Is There Hope After 5-FU Bolus? A Phase II Study of Short Term Protracted Infusion of High Dose 5-Fluorouracil (5-FU) with Leucovorin (LV) and Low Dose

Phosphonacetyl-L-Aspartic Acid (PALA) in Colorectal Carcinoma. Proc. ASCO, 186, May 1992, (abs #558).

- 39) Abdel-Nabi, H. Serafini, A. DeJager, R. Cuba-Vargas, R. Subramanian, R. Evans, N. Moffat, F. Farrell, E. McCabe, R. Mepani, B. **Benedetto, P.** Hanna, Jr. MG. Scintigraphy of Colorectal Cancers with Human Monoclonal Antibody (MoAb) 888BV59H21 (88BV): A Phase II Clinical Trial. Proc ASCO, 184, May, 1992, (abs # 551).
- 40) Feun, LG. Reddy, KR. Yrizarry, JM. Savaraj, N. Guerra, JJ. Purser, RK. Waldman, S. Moffat, F. Morrell, L. Ardalan, B. and **Benedetto, P.** Phase I Chemoembolization with Cisplatin and Lipiodol for Primary and Metastatic Liver Cancer. Proc. AACR, May 1992.
- 41) Feun, LG. Reddy, KR. Yrizarry, JM. Savaraj, N. Guerra, JJ. Purser, RK. Waldman, S. Moffat, F. Morrell, L. Ardalan, B. **Benedetto, P.** Phase I Chemoembolization trial with Cisplatin and Lipiodol. Proc. AACR, 230, May 1992, (Abs # 1376).
- 42) Sridhar, Ks. Krishan, A. Samy, TSA, Wellham, LL. McPHee, G. Sauerteig, A. Duncan, RC Waldman, S. and **Benedetto, P.** Prochlorperazine as a doxorubicin efflux blocker: Phase I and pharmacokinetic studies. Proc AACR, 213, Mar 1993, (abs #1272).
- 43) Ganz, WI, Nguyen, TQ. Mnaymneh, W. **Benedetto, P.** Friden, A. Topchik, S. Serafini, A. Sfakianakis, G. Use of Early, Late and SPECT Thallium imaging in evaluating activity of soft tissue and bone tumors. Proc, Soc of Nucl Med, 1993.
- 44) Serafini, AN. Vargas-Cuba, R. Moffat, F. **Benedetto, P.** Ardalan, B. Dewanjee, MK. DeJager, R. Sfakianakis, G. Radioimmunosintigraphy (RIS) of Colorectal cancer with Tc-99m-IgG3 labeled whole human monoclonal antibody (HMoAb) 88BV59. Proc Soc of Nucl Med, 1993.
- 45) Serafini, AN. Vargas-Cuba, R. Moffat, F. Levi, J. Livingstone, JA. Hanna, M. **Benedetto, P.** Ardalan, B. Miller, CL. Crichton, G. Wessner, B. Klein, J. Sridhar, K. Dewanjee, MK. Sfakianakis, G. DeJager, R. Radioimmunosintigraphy (RIS) of Colorectal Cancer with Tc-99m-IgG3 labeled whole human monoclonal antibody (HuMoAb) 88BV59. Proc. Eur Assoc of Nucl Med Congress, 1993.
- 46) Flores, R. Morrell, L. Richman, S. Waldman, S. Hurley, J. Mies, C. **Benedetto, P.** Feun, L. Donofrio, K. Liebman, A. Hanlon, J. Cassileth, P. Neoadjuvant Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) for Locally Advanced Breast Cancer (LABC). Proc. ASCO, 102, May 1993 (Abs# 211).
- 47) Sridhar. KS. Krishan, A. Ucar, A. Samy, TSA. Elie-Auguste, M. Sauerteig, A. McPhee, G. Ramachandran, C. **Benedetto, P.** Garcia, J. Phase I Clinical And Pharmacokinetic Study of Escalating Doses of Dipyridamole and a Fixed Dose of Doxorubicin. Proc. ASCO, 164, May, 1993 (abs # 456).

- 48) Whitehead, RP. Wolf, MK. Solanki, DL. **Benedetto, P.** Flanagan, RC. Crawford, ED. A Phase II Trial of Continuous infusion recombinant Interleukin-2 (rIL-2) in Patients with Advanced Renal Cell Carcinoma. Proc ASCO, 253, May 1993, (abs# 799).
- 49) Feun, LG. Savaraj, N. **Benedetto, P.** Reddy, R. Jeffers, L. Schiff, E. Levi, J. Livingstone, A. Sridhar, KS. Hung, S. Phase II trial of leukocyte interferon plus doxorubicin in advanced hepatoma. Proc AACR, 208, Mar 1993, (abs #1242).
- 50) Sridhar, KS. Krishan, A. Ucar, A. Samy, TSA. Byrnes, J. **Benedetto, P.** Garcia, J. Hussein, A. Phase I Study of Dipyridamole as an Efflux Blocker of Doxorubicin. Proc ASCO, 154, Mar, 1994. (abs #411).
- 51) **Benedetto, P.** Mnaymneh, W. Ghandur-Mnaymneh, L. Wolfson, A. Neoadjuvant Chemotherapy for Nonmetastatic Extremity Soft Tissue Sarcomas. Proc. Joint Meeting EMSOS-AMSTS, Florence, Italy, May, 1995. p.76.
- 52) A Restrepo. T Johnson. GE Byrne, Jr. **P Benedetto.** CC Whitcomb. D Tse. W Voight. PA Cassileth. Central nervous system prophylaxis is unnecessary in ocular adnexal lymphoma. Blood: Proc Am Soc Hem, Vol 88, No.10 suppl., p.227a, 1996.
- 53) Sridhar, KS. Krishan, A. Baldie, P. Rehman, JA. **Benedetto, P.** Cassileth, P. Fernandez, H. Do Doxorubicin efflux blockers work in the Clinic? University of Miami Medical School, Miami, FL. Proc. ASCO Vol 16, p. 251a, 1997. (abs. #887)
- 54) Pasquini, M. Raez, L. Bathe, O. Raub, Merchan, J. Caldera, H. Levi, J. **Benedetto, P.** Preoperative Biliary Stents (PBS) in Patients with Tumors of the Ampulla of Vater. Pro ASCO 18: 296a, 1999. (Abs. 1138)
- 55) Tumors of the Ampulla of Vater: Outcome and Prognostic Factors for Survival. Raez, L. Pasquini, P. Mrechan, J. Raub, W. Bathe, O. Caldera, H. Levi, J. **Benedetto, P.** Pro ASCO 18: 298a, 1999 (abs 1143)
- 56) Second Primary Tumors after Multimodality Treatment of Non-Small Cell Lung Carcinoma Markoe, Arnold m. Sridhar, Kasi S. Kaul, Paritosh. Thurer, Richard J. **Benedetto, Pasquale.** Ganjei-Azar, Parvin. Donna, Elio. Hurley, Judith. Donnelly, Elizabeth. Fountzilas, George. Krishan, Awtar. Pro ASCO 18: 516a, 1999. (abs 1990)
- 57) Gemcitabine: an active chemotherapeutic agent for angiosarcoma. Umang Gautam, Judith Hurley, Orlando E Silva, **Pasquale W Benedetto,** Carlos Robles, University of Miami, Miami, FL; Dept of Veterans Affairs, Miami, FL. Proc Am Soc Clin Oncol 21: 2002 (abstr 2931)
- 58) Neoadjuvant chemotherapy for adult, nonmetastatic, intermediate (G2) or high grade (G3) appendicular soft tissue sarcoma Gustavo L Fernandez, **Pasquale Benedetto,** University of Miami-Sylvester Cancer Center, Miami, FL. Proc Am Soc Clin Oncol 21: 2002 (abstr 2943)

- 59) J. P. Dutcher, C. Szczylik, N. Tannir, P. **Benedetto**, P. Ruff, A. Hsu, A. Berkenblit, A. Thiele, A. Strahs, J. Feingold Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5033
- 60) Tarek Mekhail¹, Ram Ganapathiz², Leila Alland³, Claude George, **Pasquale Benedetto**, Lisa Iacono A Phase I Study of the Alternating Administration of Ixabepilone and Vinflunine Every Three Weeks in Patients with Advanced Cancer AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, Boston, MA, 2009
- 61) V. D. Guardiola Amado, A. J. Montero, A. Ferrell, A. M. Flores, M. Vulfovich, M. D. Pegram, **P. W Benedetto**, C. S. Rocha Lima, J. R. Merchan; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL; Memorial Cancer Institute, Hollywood, FL Phase I trial of weekly and every-three-weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs). J Clin Oncol 28, 2010 (suppl; abstr e13516)
- 62) M. Kittaneh, A. J. Montero, K. Kovacs, V. D. Guardiola Amado, A. M. Flores, A. Ferrell, M. Vulfovich, M. D. Pegram, **P. W. Benedetto**, C. M. S. Rocha Lima, J. R. Merchan; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL; University of Miami, Miami, FL; University of Miami Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL; Memorial Cancer Institute, Hollywood, Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs). J Clin Oncol 29: 2011 (suppl; abstr 3081) Poster- Developmental therapeutics
- 63) Gustavo L. Fernandez, David J. Vaughn, Andrew V. Schally, Tulay Koru-Sengul, Jaime R. Merchan, Aurea M. Flores, Merce Jorda, **Pasquale W. Benedetto**, Rakesh Singal, Norman L. Block Phase 1 trial of zoptarelin doxorubicin (Zop-Dox) in advanced unresectable or metastatic urothelial carcinoma (UC) patients who failed platinum-based chemotherapy. Citation: J Clin Oncol 32, 2014 (suppl; abstr e15517)

Collaborative Studies:

- 64) Douglass Jr, HO. Stablein, DM. for the Gastrointestinal Tumor Study Group (GITSG). A Randomized Comparison of Radiation plus Streptozotocin + Mitomycin + 5-Fluorouracil (SMF) versus SMF alone for Therapy of Local Unresectable Carcinoma of the Pancreas. Proc. ASCO, 1986.
- 65) Blum, R. LaFleur, F. Green, MD. Dubon, N. Shemans, I. and the Rectal Study Group. Feasibility of Prospective Quality of Life Assessment (QLA) in Phase III Trial of Epirubicin (Epi-ADM) vs. 5-Fluorouracil (F) in Sigmoid and Rectal Carcinoma. Proc. ASCO, 1986.

- 66) Neidhart, J. Harris, J. Tuttle, R. M.D. Anderson Hospital and Tumor Institute, Houston, Texas; Rush Presbyterian St. Luke's Medical Center, Chicago, Ill.; Burroughs Wellcome Research, Triangle Park, N.C. Ten Participating Institutions: A Randomized Study of Wellferon (WFN) With or Without Vinblastine (VLB) in Advanced Renal Cancer. Proc. ASCO, #939, 1987.
- 67) Smalley, R. Tuttle, R. Whisnant, J. Anderson, S. Huang, A. Connors, J. and other participating Investigators: Effectiveness of Alpha-n-I-IFN, an Ultra Low Dose in the Treatment of Hairy Cell Leukemia Ca (HCL). Proc. ASCO, 1987.
19. Other works accepted for publication:

PROFESSIONAL

20. Editorial Responsibilities: NONE

21. Professional and Honorary Organizations:

- American College of Physicians, Member
- American Society of Clinical Oncology (ASCO), Member
- American Association for the Advancement of Science, Member
- American Association of Cancer Research (AACR), Member
- Eastern Cooperative Oncology Group (ECOG), Member
- National Surgical Adjuvant Breast Cancer Study Group, Member
- Greater Miami Oncology Society, Member

22. Honors and Awards:

-Phi Beta Kappa, Georgetown University, Washington, D.C.

-Miljevic Medal for Highest Achievement, Department of Chemistry, Georgetown University, Washington, D.C.

-Summa Cum Laude, Georgetown University, Washington, D.C.

-Dade County Medical Association Alliance Foundation and Dade County Medical Association Award for Clinical Oncology , March, 1996.

Iron Arrow, University of Miami Honor Society , October 2003

23. Post-Doctoral Fellowships: NONE

24. Other Professional Activities

Scientific Presentations:

Prognostic Significance of Terminal Deoxynucleotidyl Transferase (Tdt) Activity Adult Nonlymphoblastic Leukemia (ANLL): Evidence for Biphenotypic Leukemias. 73rd Annual Meeting of the American Association for Cancer Research, St. Louis, MO, April, 1982

Phase II Trial of Continuous Infusion Chemotherapy in Prior Untreated Patients with Metastatic Colorectal Cancer. National Surgical Adjuvant Breast Cancer Meeting, San Francisco, February 1986.

Neoadjuvant Chemotherapy in the Management of Appendicular Soft Tissue Sarcomas. Third International Congress of Neoadjuvant Chemotherapy. Paris, France. Feb 1991.

Neoadjuvant Chemotherapy for Nonmetastatic Extremity Soft Tissue Sarcomas. Joint Meeting EMSOS-AMSTS. Florence, Italy, May, 1995

Invited Outside Lectureships:

- 1) **Advances in Chemotherapy and Treatment of Lung Cancer.** IV Jornada Medica de Aniversario, Junta de Beneficencia de Guayaquil, Hospital Luis Vernaza, Guayaquil, Ecuador, November 1982.
- 2) **Advances in Cancer Chemotherapy.** International Medical Center, Miami, Florida, September 1982.
- 3) **Chemotherapy of GI Malignancies.** Lukes Cancer Center at Morton F. Plant Hospital, Tampa, Florida, February 1984.
- 4) **Update in Chemotherapy: Regional and Continuous Systemic Infusion, Biochemical Modulation.** Mt. Sinai Medical Center, Miami, Florida, December 1984.
- 5) **New Concepts in Oncology.** Kuwait Cancer Control Center, Kuwait City, Kuwait, March 16-19, 1985.
 - Principles of Clinical Trials in Oncology
 - Role of Clinical Trials in the Development of Cancer Management
 - Intra-arterial Chemotherapy for Liver Metastases
 - Continuous Infusion Chemotherapy

Responsibilities of a Medical Oncologist

- 6) **Chemical Modulation of Antineoplastic Therapy.** VA Medical Center, Miami, Florida, August 24, 1985.
- 7) **Interpretation of Markers for Germ Cell Tumors of the Testis.** Sixth Annual Cancer Conference and Seminar, American Cancer Society, Long Boat Key, Sarasota, Florida, May 1986.
- 8) **Management of Bladder Cancer.** Halifax Hospital, Daytona Beach, Florida, 1986.
- 9) **Update in the Management of Metastatic Bladder Cancer: "Neoadjuvant Chemotherapy for Bladder Cancer.** Annual Meeting Florida Society of Clinical Oncologists (FLASCO) sponsored by American Cancer Society, 1986.
- 10) **Clinical Applications of Interferon.** Palm Beach Gardens Hospital, Palm Beach, Florida, September 1986.
- 11) **Use of Interferon in Clinical Practice.** Hollywood Memorial Hospital, Hollywood, Florida, September 1986.
- 12) **Treatment of Renal Cell Carcinoma with Interferon.** St. Francis Hospital, Miami Beach, Florida, April 1987.
- 13) **Continuous Infusion Chemotherapy in Colorectal Cancer.** Sixth Annual Oncology Seminar, Mercy Hospital, Ocho Rios, Jamaica, May 1987.
- 14) **Pharmacologic Advances in Oncology.** Annual Pharmacology Symposium, South Miami and Baptist Hospitals, Miami, Florida, June 1, 1987.
- 15) Department of Urology Postgraduate Seminar in Pediatrics and Adult Urology Course:
1985 **Management of Metastatic Renal Cell Carcinoma**
1986 **Tumor Markers in Testis Cancer**
1987 **Chemotherapy of Prostatic Cancer**
1990 **The Role of Chemotherapy and Expectant Management in Non-seminomatous Tumors**
The Role of Chemotherapy in Advanced Seminomas
- 16) **Chemotherapy in the Management of Prostate Cancer.** 10th Annual Oncology Update. Cedars Medical Center, Feb., 1988.
- 17) **Update on Management of Bone and Soft Tissue Sarcomas.** 7th Annual Oncology Seminar, Mercy Hospital, San Jose, Costa Rica, May, 1988.

- 18) **Update on the Management of Testicular Cancer.** 8th Annual Oncology Seminar, Mercy Hospital, Grand Cayman Islands, May 1989
- 19) **Oncology Update.** Internal Medicine Review Course co-sponsored by University of Texas Health Science Center and the Osler Institute, September 9, 1989.
- 20) **Update on the Management of Gastrointestinal Cancer.** Annual Meeting of the Southern Medical Association, Washington, D.C., Oct. 1989.
- 21) **Multimodal Management of Soft Tissue Sarcomas.** 9th Annual Cuban American Medical Association Congress. Miami, Florida, June 1991.
- 22) II Congreso Boliviano De Medicina Interna, VII Curso Internacional Del American College of Physicians, La Paz, Bolivia, May 5-8, 1992:
-Treatable Cancers in 1992
- 23) Bolivian Cancer Society Meeting, Cochabamba, Bolivia May 1992
-Treatable Cancers in 1992
-Update on the Management of Colorectal Cancer
-Management of Soft Tissue Sarcomas
- 24) **Management of Osteogenic Sarcoma** , Luis McKenna Hospital for Children, Santiago, Chile. May, 1992.
- 25) Fundamental and Clinical Aspects of Internal Medicine, 19th Annual Board review Course in Internal Medicine, **Gastrointestinal Cancer and Genitourinary Cancer**, August, 1992.
- 26) **Lymphomas.** Internal Medicine Update, Miami Beach, Florida February 1994
- 27) **Clinical Management of Soft Tissue and Bone Tumors.** 20th Annual Review and Recent Practical Advances in Pathology. Miami Beach, Florida, February, 1995.
- 28) **Role of Neoadjuvant Chemotherapy, Panel Discussion.** Internal Medicine Update. Miami Beach, Florida, February, 1996
- 29) **Challenging Cases in Urology, Testis Section.** Bal Harbour, Florida , March, 1996.
- 30) **Breast Cancer Workshop**, Department of Medicine 31st Annual Postgraduate Course. Miami Beach, Florida, May 1996.
- 31) **Challenging Cases in Urology, Bladder, Testis and Renal Sections**, Bal Harbour, February ,1997

- 32) **Managing Career and Cancer, What You Need to Know.** Hotel Inter-Continental, Miami, Florida, November, 1997, Sponsored by Amgen
- 33) **Challenging Cases in Urology, Bladder, Testis, Prostate Sections.** Bal Harbour, Florida , February, 1998.
- 34) **Diagnosis and Treatment of Sarcomas.** Florida Tumor Registrar Association (FTRA) Oncology Workshop, June, 1999.
- 35) **Challenging Cases in Urology, Bladder Section.** Orlando, Florida, February 2001
- 36) Joint Cancer Conference of the Florida Universities, **Chemotherapy of Prostate Cancer**, Orlando , Florida , February, 2001
- 37) Novartis Oncology Training and Development Conference, **Overview of Gastrointestinal Tumors.** Orlando, Florida, January, 2007.
- 38) 33rd Annual Review and Recent Practical Advances in Pathology. **Clinical Management of Kidney Tumors**, Miami Beach, Florida, January , 2008.
- 39) EMO IV Congress, **Update in the Management of Renal Cell Carcinoma**, Acapulco , Mexico, September, 2009.
- 40) New Orleans Annual Cancer Meeting
 - 2011 Targeted Therapy in the Treatment of Sarcomas
 - 2012 Biological Insights and Novel Applications in Soft Tissue Sarcomas.
 - 2013 Targets in the treatment of Soft tissue Sarcomas
 - 2014 Biological insights and novel therapies in soft tissue sarcomas

On Campus Conferences:

- 1982-1986 Biology of Cancer Course: Undergraduate Division, University of Miami School of Medicine
- 1984-Pres Oncology Course for "Fundamental and Clinical Aspects of Internal Medicine: Annual Review Course for Certification in Internal Medicine"
- 1983-1986 "Pharmacology of Antineoplastic Agents" Chemotherapy Administration Workshop: Department of Nursing Education.
- 1987-1990 Mechanisms of Disease Course Participant, Second Year Medical School curriculum

- 1993 Immunotherapy of Metastatic Renal Cell Carcinoma
 Florida Tumor Registrars Association Regional Workshop, July

Urology Grand Rounds:

- 1984 Carcinoma of the Testis
- 1985 Update on the Treatment of Carcinoma of the Bladder
- 1986 Treatment of Renal Cell Carcinoma
- 1990 Neoadjuvant Chemotherapy of Bladder Cancer
- 1991 UM experience with Interleukin-2 and Metastatic Renal Cell Carcinoma

Oncology Board Review Course for Residents, 1984

Morbidity and Mortality Conferences:

- . Mediastinal Germ Cell Tumor
- . Testicular Carcinoma
- . Non Epidemic Kaposi's Sarcoma
- . Renal Cell Carcinoma
- . Evaluation of the Patient with Unknown Primary
- . Hepatoma
- . Osteosarcoma and Paget's Disease
- . Microangiopathic hemolytic anemia associated with adenocarcinoma of stomach
- . Chorionepithelioma of stomach
- . Pancreatic Carcinoma
- . Carcinomatous Meningitis and Bladder Cancer
- . Retroperitoneal Fibrosis
- . Retroperitoneal Sarcoma
- . Primary Soft Tissue Sarcoma of the Foot
- . Unusual Presentation of Multiple Myeloma

Department of Medicine Grand Rounds, Testicular Cancer. February 23, 1994.

TEACHING (see Above)

25. A. Teaching Awards Received:

Medical Oncology Attending Rotation Department of Medicine Housestaff Evaluations
Consistently "Superior"

B. Current Teaching Responsibilities

Inpatient Hematology-Oncology Ward Medical Attending at the Jackson Memorial Hospital (JMH) WW12 5 periods/year

Oncology Consult attending JMH 3 periods/year

Coordinator of Hematology-Oncology Module (September, February) for second year medical students

26. Thesis and dissertation advising: NONE

SERVICE

27. University Committee and Administrative Responsibilities

Honors Program in Medical Education (B.S.-M.D.) Committee -
Committee Member 1987-1996, Chairman 1996-Present

Participation on this committee requires a multihour commitment of time between November and April each year to review the applications of and interview high students applying to medical school through the HPME 6 year pathway. The committee meets regularly during this time to rank each of the students chosen by the individual faculty members for admission, award scholarships, approve student requests for additional study, determine program policy, etc. In addition this committee also is responsible for the Medical Scholars Programs

As Chairman of the Committee in addition to the above duties, I am responsible for arranging the annual schedule, interfacing with Admissions Office on main campus to coordinate committee activities, reviewing the academic record and counselling students in academic difficulty, overseeing the balloting and voting procedure for both HPME and MSP programs, orienting new members to committee responsibilities.

DEPARTMENT ADMINISTRATIVE AND COMMITTEE RESPONSIBILITIES

Program Director, Fellowship Training and Education, 1986-1992; 1997-2014
Associate Program Director 2014-

Responsibilities include:

* recruitment of new fellows to the medical oncology training program, review of applications, interview scheduling, preparation of descriptive materials, correspondence

- * coordination of the educational experience of the current fellows including clinic supervision, conference preparation guidance, attending rotation
- * advising fellows on the preparation of a manuscript for publication which is a requirement for successful completion of the program
- * evaluation of the fellow's academic performance which includes a quarterly review interview to provide ongoing input on attributes and areas for improvement including feedback on the fellows perception of the strengths and weaknesses of the program
- * preparation of yearly schedule including restructuring as needed to improve program goals and comply with graduate medical education accreditation
- * preparation of the application for certification of the fellowship program by the association of graduate medical education (AGME)
- * coordination of the weekly multi-disciplinary Tumor Board which requires identification of cases, preparation of a short clinical case summary, and notification of radiology, pathology, and surgery staff among others

Director of Clinical Services, Department of Oncology, 1990-1992

Responsibilities include:

- * Medical Director of the inpatient Oncology Ward (WW12) which involves policy making for clinical care, control of the admissions process, monthly triad meetings with nursing administration for coordination of services and project development
- * recruitment of nurse research personnel, data managers, support staff within the department. Includes supervision of all such ancillary with periodic evaluation of efficiency, productivity, and distribution of resources; formulation and interpretation of job description; arbitration of conflicts
- * liaison between department faculty and hospital staff (OPD-3) for smooth and proper function of the clinic, includes a monthly meeting with nursing administration and invited guests to provide ongoing forum for change
- * member of a committee for the ongoing development of a psychosocial support service at JMH and NCCH which includes quarterly meetings with members of the Departments of Psychiatry, Psychology, Social Work, Nursing

Director OPD Hematology-Oncology Clinic Services 1992-2000

Medical Director JMH Oncology Ward, 1990-Present

Executive Committee, Jackson Memorial Hospital 1996-1999.

Service Chiefs Committee, University of Miami Hospital Sylvester Cancer Center 1996-2000

UMMG Benefits and Personal Committee, Oct 1999-

28. Community Activities

Hematology/Oncology Consultant to Children's Medical Services, Department of Health & Rehabilitative Services, State of Florida